CLIN CANCER RES:RCC2过表达促进肺腺癌转移

2017-09-24 MedSci MedSci原创

CLIN CANCER RES近期发表了一篇文章,研究RCC2在肺腺癌转移中扮演的角色。

CLIN CANCER RES近期发表了一篇文章,研究RCC2在肺腺癌转移中扮演的角色。作者使用临床肿瘤标本评估RCC2对肺腺癌转移的影响。使用鼠模型、细胞生物学、分子生物学等手段阐明RCC2在肺腺癌中的功能及其作用机制。研究结果表明,在肺腺癌中RCC2表达普遍上调(88/122,72.13%)。通过分析包含了488例肺腺癌和58例正常肺组织的TCGA RNA-seq数据进一步验证了这一结果。RCC2水平升高与肿瘤T分期,淋巴结转移和晚期临床分期显着相关。RCC2表达水平更高的肺腺癌患者总生存期更短。Cox回归分析结果表明RCC2是肺腺癌患者不良预后的独立预测因素。此外,体内实验中人为增加RCC2表达可以促进肿瘤肺内转移,在体外实验中则可以显着促进肺腺癌细胞迁移、侵袭和增殖。进一步研究表明RCC2可以诱导上皮细胞间质转化(EMT),并可以刺激MMP-2和MMP-9表达。此外,RCC2可以激活JNK,阻断JNK可以抑制RCC2对肺腺癌细胞迁移、侵袭、EMT和MMP-2、MMP-9的影响。文章最后认为,RCC2通过激活MAPK-JNK信号通路诱导上皮细胞间质化在肺腺癌转移中起到了重要的作用

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2036672, encodeId=ff5320366e265, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Nov 09 04:01:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958166, encodeId=d529195816620, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Mar 20 12:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590303, encodeId=2584159030301, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Sep 26 00:01:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247399, encodeId=c41324e3999b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Sep 25 00:35:18 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247309, encodeId=cae124e309bd, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Sep 24 13:59:45 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247263, encodeId=b31024e26337, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 24 11:29:58 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2017-11-09 isabellayj
  2. [GetPortalCommentsPageByObjectIdResponse(id=2036672, encodeId=ff5320366e265, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Nov 09 04:01:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958166, encodeId=d529195816620, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Mar 20 12:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590303, encodeId=2584159030301, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Sep 26 00:01:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247399, encodeId=c41324e3999b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Sep 25 00:35:18 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247309, encodeId=cae124e309bd, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Sep 24 13:59:45 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247263, encodeId=b31024e26337, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 24 11:29:58 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2018-03-20 lq1767
  3. [GetPortalCommentsPageByObjectIdResponse(id=2036672, encodeId=ff5320366e265, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Nov 09 04:01:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958166, encodeId=d529195816620, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Mar 20 12:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590303, encodeId=2584159030301, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Sep 26 00:01:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247399, encodeId=c41324e3999b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Sep 25 00:35:18 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247309, encodeId=cae124e309bd, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Sep 24 13:59:45 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247263, encodeId=b31024e26337, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 24 11:29:58 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2017-09-26 linagood
  4. [GetPortalCommentsPageByObjectIdResponse(id=2036672, encodeId=ff5320366e265, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Nov 09 04:01:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958166, encodeId=d529195816620, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Mar 20 12:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590303, encodeId=2584159030301, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Sep 26 00:01:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247399, encodeId=c41324e3999b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Sep 25 00:35:18 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247309, encodeId=cae124e309bd, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Sep 24 13:59:45 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247263, encodeId=b31024e26337, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 24 11:29:58 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2017-09-25 luominglian113

    学习了.谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2036672, encodeId=ff5320366e265, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Nov 09 04:01:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958166, encodeId=d529195816620, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Mar 20 12:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590303, encodeId=2584159030301, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Sep 26 00:01:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247399, encodeId=c41324e3999b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Sep 25 00:35:18 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247309, encodeId=cae124e309bd, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Sep 24 13:59:45 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247263, encodeId=b31024e26337, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 24 11:29:58 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2017-09-24 131****1460

    学习了受益匪浅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2036672, encodeId=ff5320366e265, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Nov 09 04:01:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958166, encodeId=d529195816620, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Mar 20 12:01:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590303, encodeId=2584159030301, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Tue Sep 26 00:01:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247399, encodeId=c41324e3999b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Sep 25 00:35:18 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247309, encodeId=cae124e309bd, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Sep 24 13:59:45 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247263, encodeId=b31024e26337, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 24 11:29:58 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2017-09-24 1e0f8808m18(暂无匿称)

    好文章.学习了.

    0

相关资讯

SCI REP:伴COPD的肺腺癌患者LRP1B突变率更高

慢性阻塞性肺病(COPD)以及肺癌是常见的肺部疾病,常共同发生。有研究表明COPD会增加肺癌发生的风险,这一现象表明COPD与肺癌发生之间存在着某种联系。人们提出了多种理论如氧化应激、遗传易感性、表观遗传学改变、炎性环境改变等来联系COPD与肺癌,但是COPD与肺癌发生之间联系的分子机制尚不明确。

Plos One:预测培美曲塞加铂类对晚期肺腺癌患者疗效的新方法!

目前,虽然培美曲塞加顺式/卡铂已经成为晚期肺腺癌患者最有效的化疗方案,但是,相关预测性生物标志物尚不可用,因此,迫切需要一项能够鉴定潜在受益于此治疗方案的敏感性患者的新工具。近期,一项发表在杂志Plos One上的研究使用两个数据库中的血清肽图谱构建并验证了预测肽模型。此项研究回顾性分析了使用以铂类为基础联合培美曲塞作为一线治疗的138例晚期肺腺癌患者,并随机分入构建组(n = 92)或验证组(n

J Thorac Oncol:病灶≤3cm、淋巴结阴性根治性手术肺腺癌的预后因素分析

目前多个有关NSCLC的指南,都没建议病灶≤3cm、淋巴结阴性肺癌根治性手术后行辅助化疗。而关于这一类肿瘤的不同组织亚型,不同形态特征及不同病灶大小亚群的各自预后情况,目前相关研究也较少。最近,台北荣民总医院洪荣志等在Journal of Thoracic Oncology发文,对这一问题进行了探讨。

CLIN CANCER RES:循环肿瘤DNA指导晚期肺腺癌治疗

肺癌目前是美国最主要的癌症死亡原因。非小细胞肺癌是最常见的病理类型。尽管早期检测及标准治疗水平均有所提高,但是非小细胞肺癌发现时往往较晚且预后不良。CLIN CANCER RES近期发表了一篇文章,研究非小细胞肺癌患者血液中循环肿瘤DNA(ctDNA)基因改变并与临床特征和治疗结果相联系。

CLIN CANCER RES:GABBR2可以作为EGFR19缺失肺腺癌的治疗靶点

过去的几十年中,人们见证了 个体化靶向治疗肺癌的快速进展。但是EGFR突变肺癌对TKI治疗的反应是否涉及到遗传学改变尚不清楚。CLIN CANCER RES近期发表了一篇文章,研究了这个问题。

J Natl Cancer Inst :美研究显示“轻型”香烟会增加患肺腺癌风险

据美国“侨报网”5 月 22 日报道,一项发表在《国家癌症研究所杂志》(the Journal of the National Cancer Institute)上的研究表明,所谓的“轻型”香烟不仅有害健康,还可能导致患肺腺癌 (肺癌的一种) 的风险增加。